Principal Financial Group
VRDN icon

Principal Financial Group’s Viridian Therapeutics VRDN Stock Holding History

Principal Financial Group’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-75,200
Closed -$1.47M – 2265
2026
Q1 		$1.47M Sell
75,200
-100,730
-57% -$2.99M ﹤0.01% 1871
2025
Q4 		$5.47M Sell
175,930
-37,399
-18% -$1.03M ﹤0.01% 1585
2025
Q3 		$4.6M Buy
213,329
+9,493
+5% +$171K ﹤0.01% 1618
2025
Q2 		$2.85M Sell
203,836
-5,000
-2% -$67.9K ﹤0.01% 1734
2025
Q1 		$2.82M Buy
208,836
+30,392
+17% +$518K ﹤0.01% 1704
2024
Q4 		$3.42M Buy
178,444
+5,634
+3% +$123K ﹤0.01% 1692
2024
Q3 		$3.93M Buy
172,810
+162,665
+1,603% +$2.66M ﹤0.01% 1634
2024
Q2 		$132K Sell
10,145
-1,770
-15% -$24.5K ﹤0.01% 2198
2024
Q1 		$209K Buy
11,915
+1,058
+10% +$20.5K ﹤0.01% 2169
2023
Q4 		$236K Sell
10,857
-199
-2% -$3.14K ﹤0.01% 2120
2023
Q3 		$170K Buy
11,056
+222
+2% +$4.24K ﹤0.01% 2192
2023
Q2 		$258K Buy
10,834
+819
+8% +$21K ﹤0.01% 2116
2023
Q1 		$255K Sell
10,015
-114
-1% -$3.65K ﹤0.01% 2127
2022
Q4 		$296K Buy
+10,129
New +$233K ﹤0.01% 2102

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Principal Financial Group's VRDN Position: Q2 2026 in Review

Principal Financial Group sold out of Viridian Therapeutics (VRDN) in Q2 2026, closing a stake of 75,200 shares — an estimated $1.47M sold.

Principal Financial Group first reported a position in VRDN in Q4 2022 and held it in 14 quarters. The position peaked at $5.47M in Q4 2025. 215 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Principal Financial Group reported no remaining Viridian Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Principal Financial Group sold 75,200 Viridian Therapeutics shares in Q2 2026, an estimated $1.47M.
  • Principal Financial Group first reported a position in Viridian Therapeutics in Q4 2022 and held it in 14 quarters.
  • Principal Financial Group's Viridian Therapeutics position peaked at $5.47M in Q4 2025.
  • 215 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Principal Financial Group's 13F filing for Q2 2026, filed 4 Aug 2026.